1. ZHAW digitalcollection
  2. School of Management and Law
  3. Publikationen
  4. Publikationen School of Management and Law
Please use this identifier to cite or link to this item: https://doi.org/10.21256/zhaw-4765
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKessler, Reto-
dc.contributor.authorKeusch, Gérard-
dc.contributor.authorSzucs, Thomas-
dc.contributor.authorWittenborn, John-
dc.contributor.authorHoerger, Thomas-
dc.contributor.authorBrügger, Urs-
dc.contributor.authorWieser, Simon-
dc.date.accessioned2018-11-09T10:26:20Z-
dc.date.available2018-11-09T10:26:20Z-
dc.date.issued2012-
dc.identifier.issn1424-7860de_CH
dc.identifier.issn1424-3997de_CH
dc.identifier.issn0036-7672de_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/12712-
dc.description.abstractPrinciples: Current evidence indicates that chronic kidney disease (CKD) can be detected by simple laboratory tests. This study aimed to evaluate the cost-effectiveness of microalbuminuria screening and subsequent treatment in different populations. Methods: Cost-effectiveness of microalbuminuria screening in a cohort of simulated subjects aged ≥50 years was assessed using a validated microsimulation model. Microalbuminuria screening was simulated for 1-, 2-, 5- or 10-year intervals and for 3 groups: diabetes (DM), hypertension but no diabetes (HTN), and no diabetes or hypertension. Positive microalbuminuria screening was followed by treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs). The model outcomes evaluate costs from a health care system perspective. Results: Screening of risk groups is cost-effective at a 2-year interval for the DM group with an incremental cost-effectiveness ratio (ICER) of 54,000 CHF/ Quality Adjusted-Life-Years (QALY) and at a 5-year interval for the HTN group with an ICER of 33,000CHF/QALY . Screening of the remaining population is cost-effective at a 10-year interval with an ICER of 34,000 CHF/QALY . The ICER improves with longer screening intervals for all groups. A probabilistic sensitivity analysis (PSA) confirmed 2-year, 5-year and 10-year intervals as the most cost-effective for the DM group, the HTN group and the remaining population respectively. Conclusions: Microalbuminuria screening can be considered cost-effective starting at the age of 50 years at biannual intervals for subjects with diabetes, at 5-year intervals for subjects with hypertension and at10-year intervals for the remaining population. Our results indicate that early detection and treatment of CKD might lead to optimised patient care, and offer guidance for future implementation of CKD screening programmes.de_CH
dc.language.isoende_CH
dc.publisherEMH Schweizerischer Ärzteverlagde_CH
dc.relation.ispartofSwiss Medical Weeklyde_CH
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0/de_CH
dc.subjectAlbuminuriade_CH
dc.subjectCost-benefit analysisde_CH
dc.subjectDisease progressionde_CH
dc.subjectFollow-up studyde_CH
dc.subjectMass screeningde_CH
dc.subjectPrevalencede_CH
dc.subjectRetrospective studyde_CH
dc.subjectEconomic modelsde_CH
dc.subject.ddc362.1041: Gesundheitsökonomiede_CH
dc.titleHealth economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerlandde_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementSchool of Management and Lawde_CH
zhaw.organisationalunitWinterthurer Institut für Gesundheitsökonomie (WIG)de_CH
dc.identifier.doi10.21256/zhaw-4765-
dc.identifier.doi10.4414/smw.2012.13508de_CH
dc.identifier.pmid22307760de_CH
zhaw.funding.euNode_CH
zhaw.originated.zhawYesde_CH
zhaw.pages.end13de_CH
zhaw.pages.start1de_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume142de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
Appears in collections:Publikationen School of Management and Law

Files in This Item:
File Description SizeFormat 
Health economic modelling of the cost-effectiveness of microalbuminuria_2012_SC1.1.pdf858.18 kBAdobe PDFThumbnail
View/Open
Show simple item record
Kessler, R., Keusch, G., Szucs, T., Wittenborn, J., Hoerger, T., Brügger, U., & Wieser, S. (2012). Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland. Swiss Medical Weekly, 142, 1–13. https://doi.org/10.21256/zhaw-4765
Kessler, R. et al. (2012) ‘Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland’, Swiss Medical Weekly, 142, pp. 1–13. Available at: https://doi.org/10.21256/zhaw-4765.
R. Kessler et al., “Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland,” Swiss Medical Weekly, vol. 142, pp. 1–13, 2012, doi: 10.21256/zhaw-4765.
KESSLER, Reto, Gérard KEUSCH, Thomas SZUCS, John WITTENBORN, Thomas HOERGER, Urs BRÜGGER und Simon WIESER, 2012. Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland. Swiss Medical Weekly. 2012. Bd. 142, S. 1–13. DOI 10.21256/zhaw-4765
Kessler, Reto, Gérard Keusch, Thomas Szucs, John Wittenborn, Thomas Hoerger, Urs Brügger, and Simon Wieser. 2012. “Health Economic Modelling of the Cost-Effectiveness of Microalbuminuria Screening in Switzerland.” Swiss Medical Weekly 142: 1–13. https://doi.org/10.21256/zhaw-4765.
Kessler, Reto, et al. “Health Economic Modelling of the Cost-Effectiveness of Microalbuminuria Screening in Switzerland.” Swiss Medical Weekly, vol. 142, 2012, pp. 1–13, https://doi.org/10.21256/zhaw-4765.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.